Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

Group 1 - The current market environment makes it challenging to find value stocks, particularly in the biotech sector, where Harmony Biosciences specializes in treatments for rare diseases [1] - Harmony's pitolisant treatment, marketed as Wakix, has been financially lucrative, with significant revenue growth since its FDA approval in 2019 [2][4] - Harmony's revenue reached $160 million in the year following FDA approval, with a compound annual growth rate of around 40%, projecting nearly $870 million in sales for 2025 and over $1 billion in 2026 [4] Group 2 - Unlike many biotech firms that increase spending on pipeline research post-approval, Harmony became profitable in 2021, with net income rising over five times to $186 million in the past 12 months [5] - Despite strong financial performance, Harmony's stock price has remained flat since its IPO, partly due to concerns over the expiration of Wakix's patent in early 2030 and potential generic competition [6] - Controversies and litigation surrounding Wakix, along with long-term worries about patent cliffs and Harmony's pipeline, have negatively impacted investor sentiment [7]